Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | GUSB | P08236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10167275 | 0.88 | GABBR2 (0.44) | GABBR2GABBR1 | |
| SCHEMBL1232078 | 0.86 | GABBR2 (0.43) | GABBR2GABBR1HTR2C | |
| SCHEMBL10135353 | 0.85 | GAA (0.42) | GABBR2GABBR1HTR2CHTR2AHTR2B | |
| SCHEMBL466160 | 0.85 | GAA (0.46) | GABBR2GABBR1HTR2BCYP2C19LMNA | |
| SCHEMBL31247883 | 0.85 | GAA (0.46) | GABBR2GABBR1HTR2BCYP2C19LMNA | |
| SCHEMBL21840813 | 0.84 | GABBR2 (0.39) | GABBR2GABBR1HTR2CHTR2AHTR2B | |
| SCHEMBL10135354 | 0.83 | GABBR2 (0.41) | GABBR2GABBR1 | |
| SCHEMBL5083413 | 0.83 | GABBR2 (0.43) | GABBR2GABBR1 | |
| SCHEMBL7676603 | 0.82 | GABBR2 (0.35) | GABBR2GABBR1 | |
| SCHEMBL12901560 | 0.81 | GRM2 (0.39) | GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464739-B1 | METHODS IN CELL CULTURES, AND RELATED INVENTIONS, EMPLOYING CERTAIN ADDITIVES | BASF SE (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-8859235-B2 | Methods in cell cultures, and related inventions, employing certain additives | BASF SE (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20120164162-A1 | METHODS IN CELL CULTURES, AND RELATED INVENTIONS, EMPLOYING CERTAIN ADDITIVES | BASF SE (DE) | 2012-06-28 | — | — | US | disclosed |
| WO-2011018472-A2 | METHODS IN CELL CULTURES, AND RELATED INVENTIONS, EMPLOYING CERTAIN ADDITIVES | BASF SE (DE) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164162-A1 | METHODS IN CELL CULTURES, AND RELATED INVENTIONS, EMPLOYING CERTAIN ADDITIVES | BBOX1, NEFM, NQO1 | GABBR2 497/4885GABBR1 256/4885HTR2C 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.